LP

LB Pharmaceuticals Inc Common Stock

LBRX·NASDAQ

$27.95

+3.4%
HealthcareBiotechnology

Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.

At a Glance

Live Snapshot
Market Cap$801.51M
EPS-1.0000
P/E Ratio-27.95
Earnings Date06/25/2026

lbrx

Other Non-Cash Items

Last Annual Value

3.33M

3-Year CAGR

-33%

5-Year CAGR

-21%

10-Year CAGR

-11%

LP

LB Pharmaceuticals Inc Common Stock Competitors Analysis of Other Non-Cash Items

LBRX · NASDAQ
CompanyOther Non-Cash Items
CAGR 3Y
CAGR 5Y
CAGR 10Y
3.33M
N/AN/AN/A 
32.00K
N/A51.6%N/A
ANNX logo
Annexon, Inc.
NASDAQ:ANNX
-2.48M
N/AN/AN/A
10.77M
N/A45.4%0.2%
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
-55.90M
N/AN/AN/A
-3.21M
N/AN/AN/A
80.95M
661.9%77.3%N/A
-7.58M
N/AN/AN/A
2.90M
-7.5%18.2%N/A
-6.68M
N/AN/AN/A
KRRO logo
Korro Bio, Inc.
NASDAQ:KRRO
31.68M
106.5%N/AN/A
LP

LB Pharmaceuticals Inc Common Stock Fair Value Envelope

LBRX · NASDAQ

Our analysis suggests that LBRX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $27.95, this represents a potential HIDDEN relative to our calculated worth for LB Pharmaceuticals Inc Common Stock.

Intrinsic Value
Current Price: $27.95